Biognosys launches groundbreaking P2 Plasma Enrichment technology for unbiased, deep plasma proteomics at ASMS 2024
P2-based plasma proteomics can be used for human or for animal-model proteomics studies and clinical research.
- P2-based plasma proteomics can be used for human or for animal-model proteomics studies and clinical research.
- This novel P2 plasma proteomics method achieves a proteome coverage of 7,000 proteins in a previously published five-cancer plasma sample set, demonstrating highest reproducibility, unprecedented enrichment of low abundant proteins, and unparalleled throughput on Bruker timsTOF® HT mass spectrometers.
- “With our proprietary P2 Plasma Enrichment method, Biognosys can now significantly enhance the depth and throughput in plasma proteomics beyond what existing methods could achieve,” explains Dr. Oliver Rinner, CEO and founder of Biognosys.
- Under a previously announced strategic partnership of Biognosys and Alamar Biosciences , Biognosys will now also offer the optional combination of P2-based mass spectrometry plasma proteomics with Alamar’s targeted, mid-plex ultra-high sensitivity NULISA proteomics panels.